Literature DB >> 21937768

Identification of specific and semi-specific SIRT inhibitors through computer-aided studies.

Antonello Mai.   

Abstract

Entities:  

Year:  2011        PMID: 21937768      PMCID: PMC3227446          DOI: 10.18632/aging.100387

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


× No keyword cloud information.
NAD+-dependent lysine deacetylases (sirtuins, SIRT1-7) have emerged as potential therapeutic targets for treatment of human illnesses such as cancer, metabolic, cardiovascular and neurodegenerative diseases. Sirtuins possess deacetylase and/or mono-ADP-ribosyltransferase activity, and this activity is directed to histone as well as non-histone targets involved in transcription, metabolism, and energy homeostasis [1,2]. SIRT1, having in cells a nuclear localization, has been widely recognized to play a multifaceted, protective role in aging, metabolism, and neurodegeneration [3]. In cancer, the role of SIRT1 is highly debated. Among SIRT1/2 inhibitors, sirtinol induced senescence-like growth arrest in human breast cancer MCF-7 cells and lung cancer H1299 cells [4] and inhibited cell growth in prostate cancer [5]; cambinol induced apoptosis in BCL6-expressing Burkitt lymphoma cells [6]; salermide was well tolerated by mice at concentrations up to 100 μM and prompted tumor-specific apoptosis in a wide range of human cancer cell lines [7]; MC2141 displayed high antiproliferative activity against Raji, DLD1, and HeLa cells [8], and tenovins, identified via a yeast genetic screen for p53 activators, decreased tumor growth in vivo as single agents at low micromolar concentrations [9]. On the other hand, in some contexts SIRT1 seems to have a protective role in cancer, in particular in colon cancer. SIRT2 is a cytoplasm enzyme mainly known as α-tubulin deacetylase, highly involved in cell cycle regulation. SIRT2 crucially regulates the functions in the mitotic checkpoint elicited by mitotic stress, as well as cell death in response to DNA damage-inducing stress [10]. In addition, SIRT2 influences adipocyte differentiation by deacetylation of FOXO proteins. Despite early evidences suggested SIRT1 as the main sirtuin target to inhibit for obtaining anticancer properties, recently SIRT2 down-regulation has been described to lead to apoptosis without cell cycle arrest in HeLa cells [11]. SIRT3-5 are mithocondrial deacetylases or ADP-ribosylases (SIRT4), and control adaptive thermogenesis (SIRT3), aging (SIRT3), insulin secretion (SIRT4), and ammonia detoxification (SIRT5) [1]. Finally, SIRT6 and SIRT7 are two nuclear and nucleolar enzymes, the first involved in the control of genomic DNA stability and DNA repair as well as glucose homeostasis, the latter exerting antiapoptotic properties [1]. In this month issue of AGING, Schlicker et al. described the identification of specific and semi-specific SIRT inhibitors through virtual screening performed by docking 1990 structurally different compounds into the peptide binding pockets of crystal structures of SIRT2, −3, −5, and −6. To avoid to select compounds blocking the NAD+ binding site, that is common to all the sirtuins and could highlight non isoform-specific compounds, the four SIRTs/NAD+ complexes have been used. For each docking run, the 10 top-ranking compounds have been selected and tested against SIRT2, −3, −5, and −6. Among the 20 compounds found active, 14 were selective for SIRT2, and 6 were able to inhibit, in addition to SIRT2, one (3 compounds) or two (2 compounds) or all (1 compound) of the other tested sirtuins. Interestingly, some compounds behaved as SIRT5 and/or SIRT6 activators. Two selected SIRT2-specific inhibitors, CSC8 and CSC13, bearing a steroid scaffold were selected for further studies. Dose-response curves gave IC50 values against SIRT2 of 4.8 (CSC8) and 9.7 (CSC13) μM. Tested against SIRT1, the two compounds showed weak inhibition at 100 μM. In functional tests in HEK cells, CSC13 increased the acetyl-α-tubulin level at 100 μM, thus confirming its SIRT2 inhibition at a cellular level. Such compound in particular seems to be interesting for further development, since carrying a 2-phenylpyrimidine moiety fused to the tetracyclic gonane structure, it is not predicted to interact with nuclear receptors, and thus it should be devoid of steroid receptor-mediated side effects.
  11 in total

1.  Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors.

Authors:  Dante Rotili; Domenico Tarantino; Vincenzo Carafa; Ester Lara; Sarah Meade; Giorgia Botta; Angela Nebbioso; Jörg Schemies; Manfred Jung; Aleksey G Kazantsev; Manel Esteller; Mario F Fraga; Lucia Altucci; Antonello Mai
Journal:  ChemMedChem       Date:  2010-05-03       Impact factor: 3.466

2.  SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis.

Authors:  Yanze Li; Haruka Matsumori; Yuji Nakayama; Mitsuhiko Osaki; Hirotada Kojima; Akihiro Kurimasa; Hisao Ito; Seiichi Mori; Motonobu Katoh; Mitsuo Oshimura; Toshiaki Inoue
Journal:  Genes Cells       Date:  2010-11-09       Impact factor: 1.891

3.  Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.

Authors:  H Ota; E Tokunaga; K Chang; M Hikasa; K Iijima; M Eto; K Kozaki; M Akishita; Y Ouchi; M Kaneki
Journal:  Oncogene       Date:  2006-01-12       Impact factor: 9.867

Review 4.  Therapeutic potential of activators and inhibitors of sirtuins.

Authors:  Aneta Balcerczyk; Luciano Pirola
Journal:  Biofactors       Date:  2010 Sep-Oct       Impact factor: 6.113

5.  Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.

Authors:  Birgit Heltweg; Tonibelle Gatbonton; Aaron D Schuler; Jeff Posakony; Hongzhe Li; Sondra Goehle; Ramya Kollipara; Ronald A Depinho; Yansong Gu; Julian A Simon; Antonio Bedalov
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

Review 6.  The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation.

Authors:  Toshiaki Inoue; Masaharu Hiratsuka; Mitsuhiko Osaki; Mitsuo Oshimura
Journal:  Cell Cycle       Date:  2007-05-30       Impact factor: 4.534

Review 7.  How does SIRT1 affect metabolism, senescence and cancer?

Authors:  Christopher L Brooks; Wei Gu
Journal:  Nat Rev Cancer       Date:  2008-12-29       Impact factor: 60.716

Review 8.  Sirtuins in mammals: insights into their biological function.

Authors:  Shaday Michan; David Sinclair
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

9.  Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.

Authors:  E Lara; A Mai; V Calvanese; L Altucci; P Lopez-Nieva; M L Martinez-Chantar; M Varela-Rey; D Rotili; A Nebbioso; S Ropero; G Montoya; J Oyarzabal; S Velasco; M Serrano; M Witt; A Villar-Garea; A Imhof; A Inhof; J M Mato; M Esteller; M F Fraga
Journal:  Oncogene       Date:  2008-12-08       Impact factor: 9.867

10.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

View more
  1 in total

1.  Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents.

Authors:  Javier A Menendez; Jorge Joven; Gerard Aragonès; Enrique Barrajón-Catalán; Raúl Beltrán-Debón; Isabel Borrás-Linares; Jordi Camps; Bruna Corominas-Faja; Sílvia Cufí; Salvador Fernández-Arroyo; Anabel Garcia-Heredia; Anna Hernández-Aguilera; María Herranz-López; Cecilia Jiménez-Sánchez; Eugeni López-Bonet; Jesús Lozano-Sánchez; Fedra Luciano-Mateo; Begoña Martin-Castillo; Vicente Martin-Paredero; Almudena Pérez-Sánchez; Cristina Oliveras-Ferraros; Marta Riera-Borrull; Esther Rodríguez-Gallego; Rosa Quirantes-Piné; Anna Rull; Laura Tomás-Menor; Alejandro Vazquez-Martin; Carlos Alonso-Villaverde; Vicente Micol; Antonio Segura-Carretero
Journal:  Cell Cycle       Date:  2013-01-31       Impact factor: 4.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.